| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Dept of Health and Social Care, Brunel University, Isleworth, 2 University Hospital Aintree, Aintree NHS Trust, Liverpool, 3 Heartlands Hospital NHS Trust, Birmingham, and 4 Respiratory Medicine, St George's Hospital Medical School, London, UK
CORRESPONDENCE: S. Spencer, Dept of Health and Social Care, Brunel University, Borough Road, Isleworth TW7 5DU, UK. Fax: 44 2088918211. E-mail: Sally.Spencer@brunel.ac.uk
Keywords: Chronic obstructive pulmonary disease, exacerbation, health status, quality of life
Received: October 29, 2003
Accepted February 17, 2004
The current analysis was supported by a grant from GlaxoSmithKline, UK.
Exacerbations of chronic obstuctive pulmonary disease (COPD) are associated with worse health status. The Inhaled Steroids in Obstructive Lung Disease in Europe (ISOLDE) study showed that treatment with fluticasone propionate (FP) reduced exacerbation frequency and the rate of deterioration in health status as compared with placebo. The present study analysed these data to test whether the effect of FP on health status was attributable to its effect on exacerbations.
Rates of deterioration in St George's Respiratory Questionnaire (SGRQ) total score were obtained for 613 patients with moderate to severe COPD followed for a maximum of 3 yrs. Exacerbation rates were skewed and could not be normalised, therefore, patients were stratified into three exacerbation groups: none, infrequent (<1.65 exacerbations·yr–1) and frequent (>1.65 exacerbations·yr–1).
There were 91 patients with no exacerbations, 285 with infrequent exacerbations and 235 with frequent exacerbations. Frequent exacerbations were independently associated with a worse baseline SGRQ score (p<0.0001) and a more rapid rate of deterioration in health status (p=0.0003). Exacerbation frequency and rate of decline in forced expiratory volume in one second were independently related to the rate of deterioration in SGRQ score.
Statistical modelling showed the beneficial effect of fluticasone propionate on deterioration in health status to be largely due to its effect on exacerbation frequency.
This article has been cited by other articles:
|
|
 |
|
  O. N. Keene, P. M. A. Calverley, P. W. Jones, J. Vestbo, and J. A. Anderson Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited Eur. Respir. J., July 1, 2008; 32(1): 17 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Albert and P. M. A. Calverley Drugs (including oxygen) in severe COPD Eur. Respir. J., May 1, 2008; 31(5): 1114 - 1124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.F. Donohue, N.A. Hanania, K.A. Sciarappa, E. Goodwin, D.R. Grogan, R.A. Baumgartner, and J.P. Hanrahan Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: A one year evaluation of safety and tolerance Therapeutic Advances in Respiratory Disease, April 1, 2008; 2(2): 37 - 48. [Abstract] [PDF]
|
|
|
|
|
|
M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers Eur. Respir. J., February 1, 2008; 31(2): 416 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Wedzicha, P. M. A. Calverley, T. A. Seemungal, G. Hagan, Z. Ansari, R. A. Stockley, and for the INSPIRE Investigators The Prevention of Chronic Obstructive Pulmonary Disease Exacerbations by Salmeterol/Fluticasone Propionate or Tiotropium Bromide Am. J. Respir. Crit. Care Med., January 1, 2008; 177(1): 19 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. K. Silverman Exacerbations in Chronic Obstructive Pulmonary Disease: Do They Contribute to Disease Progression? Proceedings of the ATS, December 1, 2007; 4(8): 586 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. McGhan, T. Radcliff, R. Fish, E. R. Sutherland, C. Welsh, and B. Make Predictors of Rehospitalization and Death After a Severe Exacerbation of COPD Chest, December 1, 2007; 132(6): 1748 - 1755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. F. Rabe, S. Hurd, A. Anzueto, P. J. Barnes, S. A. Buist, P. Calverley, Y. Fukuchi, C. Jenkins, R. Rodriguez-Roisin, C. van Weel, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary Am. J. Respir. Crit. Care Med., September 15, 2007; 176(6): 532 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. A. Calverley, F. Sanchez-Toril, A. McIvor, P. Teichmann, D. Bredenbroeker, and L. M. Fabbri Effect of 1-Year Treatment with Roflumilast in Severe Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., July 15, 2007; 176(2): 154 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Azarisman, M. A. Fauzi, M. P. A. Faizal, Z. Azami, A. M. Roslina, and H. Roslan The SAFE (SGRQ score, air-flow limitation and exercise tolerance) Index: a new composite score for the stratification of severity in chronic obstructive pulmonary disease Postgrad. Med. J., July 1, 2007; 83(981): 492 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Celli and P. J. Barnes Exacerbations of chronic obstructive pulmonary disease Eur. Respir. J., June 1, 2007; 29(6): 1224 - 1238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K Johnson, M. Birch, R. Carter, J. Kinsella, and R. D Stevenson Measurement of physiological recovery from exacerbation of chronic obstructive pulmonary disease using within-breath forced oscillometry Thorax, April 1, 2007; 62(4): 299 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Rodriguez-Roisin Impacting patient-centred outcomes in COPD: exacerbations and hospitalisations Eur. Respir. Rev., December 1, 2006; 15(99): 47 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. A. Calverley Exercise and dyspnoea in COPD Eur. Respir. Rev., December 1, 2006; 15(100): 72 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kessler, E. Stahl, C. Vogelmeier, J. Haughney, E. Trudeau, C.-G. Lofdahl, and M. R. Partridge Patient Understanding, Detection, and Experience of COPD Exacerbations: An Observational, Interview-Based Study. Chest, July 1, 2006; 130(1): 133 - 142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Fernaays, A. J. Lesse, S. Sethi, X. Cai, and T. F. Murphy Differential Genome Contents of Nontypeable Haemophilus influenzae Strains from Adults with Chronic Obstructive Pulmonary Disease. Infect. Immun., June 1, 2006; 74(6): 3366 - 3374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Wedzicha and T. Wilkinson Impact of Chronic Obstructive Pulmonary Disease Exacerbations on Patients and Payers Proceedings of the ATS, May 1, 2006; 3(3): 218 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Gartlehner, R. A. Hansen, S. S. Carson, and K. N. Lohr Efficacy and Safety of Inhaled Corticosteroids in Patients With COPD: A Systematic Review and Meta-Analysis of Health Outcomes Ann. Fam. Med, May 1, 2006; 4(3): 253 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Scott, P Walker, and P M A Calverley COPD exacerbations {middle dot} 4: Prevention Thorax, May 1, 2006; 61(5): 440 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E Hollandl and B. M Buttonl Is there a role for airway clearance techniques in chronic obstructive pulmonary disease? Chronic Respiratory Disease, April 1, 2006; 3(2): 83 - 91. [Abstract] [PDF]
|
|
|
|
|
|
N. J. Stevenson, P. P. Walker, R. W. Costello, and P. M. A. Calverley Lung Mechanics and Dyspnea during Exacerbations of Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., December 15, 2005; 172(12): 1510 - 1516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D D Sin, L Wu, J A Anderson, N R Anthonisen, A S Buist, P S Burge, P M Calverley, J E Connett, B Lindmark, R A Pauwels, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease Thorax, December 1, 2005; 60(12): 992 - 997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Haughney, M. R. Partridge, C. Vogelmeier, T. Larsson, R. Kessler, E. Stahl, R. Brice, and C-G. Lofdahl Exacerbations of COPD: quantifying the patient's perspective using discrete choice modelling Eur. Respir. J., October 1, 2005; 26(4): 623 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Alvarez-Mon, M. Miravitlles, J. Morera, L. Callol, and J. L. Alvarez-Sala Treatment With the Immunomodulator AM3 Improves the Health-Related Quality of Life of Patients With COPD Chest, April 1, 2005; 127(4): 1212 - 1218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Decramer, R Gosselink, M Rutten-Van Molken, J Buffels, O Van Schayck, P-A Gevenois, R Pellegrino, E Derom, and W De Backer Assessment of progression of COPD: report of a workshop held in Leuven, 11-12 March 2004 Thorax, April 1, 2005; 60(4): 335 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Decramer, R Gosselink, P Bartsch, C-G Lofdahl, W Vincken, R Dekhuijzen, J Vestbo, R Pauwels, R Naeije, and T Troosters Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004 Thorax, April 1, 2005; 60(4): 343 - 349. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
